The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

Galmed (GLMD) announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic steatohepatitis (NASH)—occurs when fat buildup in the liver causes liver ...

NAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million in India. Left untreated, NAFLD can progress to non-alcoholic ...

and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat ...